Historique
Rapport
Assessment of the implementation of the EU Drugs Strategy 2005-2012 and its Action Plans
Auteur(s) :
CULLEY, D. M. ;
TAYLOR, J. ;
RUBIN, J. ;
HOORENS, S. ;
DISLEY, E. ;
RABINOVICH, L.
Année
2012
Page(s) :
233 p.
Langue(s) :
Anglais
Éditeur(s) :
Santa Monica, CA : Rand Corporation
Collection :
Technical Reports, TR-1228-EC
Domaine :
Drogues illicites / Illicit drugs
Discipline :
SAN (Santé publique / Public health)
Thésaurus géographique
EUROPE
;
UNION EUROPEENNE
Thésaurus mots-clés
PLANIFICATION SANITAIRE
;
EVALUATION
;
PREVENTION
;
PRODUIT ILLICITE
;
LUTTE
;
MARCHE DE LA DROGUE
;
PARTENARIAT
;
RECOMMANDATION
Note générale :
Prepared for the European Commission Directorate General for Justice
Note de contenu :
CONTENTS:
Chapter One - Introduction
• Part One: The EU Drugs Strategy and its context
Chapter Two - Background to drugs policy in the EU
Chapter Three - The EU Drugs Strategy 2005-2012
• Part Two: Assessment of the EU Drugs Strategy
Chapter Four - Demand reduction
Chapter Five - Supply reduction
Chapter Six- Coordination
Chapter Seven - International cooperation
Chapter Eight - Information, research and evaluation
• Part Three: Synthesis
Chapter Nine - Conclusions
Chapter Ten - Recommendations
Appendix A: Interview protocol - key informant interviews
Appendix B: Interview protocol - EU level in-depth interviews
Appendix C: Interview protocol - Member State level in-depth interviews
Appendix D: Questions in the EEAS survey
Appendix E: Findings from the EEAS survey
Appendix F: Online questionnaire
Appendix G: Case study objectives for implementation: data summary tables
Appendix H: List of documents consulted
Chapter One - Introduction
• Part One: The EU Drugs Strategy and its context
Chapter Two - Background to drugs policy in the EU
Chapter Three - The EU Drugs Strategy 2005-2012
• Part Two: Assessment of the EU Drugs Strategy
Chapter Four - Demand reduction
Chapter Five - Supply reduction
Chapter Six- Coordination
Chapter Seven - International cooperation
Chapter Eight - Information, research and evaluation
• Part Three: Synthesis
Chapter Nine - Conclusions
Chapter Ten - Recommendations
Appendix A: Interview protocol - key informant interviews
Appendix B: Interview protocol - EU level in-depth interviews
Appendix C: Interview protocol - Member State level in-depth interviews
Appendix D: Questions in the EEAS survey
Appendix E: Findings from the EEAS survey
Appendix F: Online questionnaire
Appendix G: Case study objectives for implementation: data summary tables
Appendix H: List of documents consulted
Résumé :
Illicit drug use continues to be an important public health and safety concern in Europe. Production, trafficking and dealing in illicit drugs constitute important criminal justice challenges in themselves, and are associated with other criminal activities. The 2005-2012 EU Drugs Strategy (as with previous strategies) was developed to complement and add value to national strategies and approaches while respecting the principles of subsidiarity and proportionality set out in the EU Treaties. The main rationale for its development was that while drugs problems vary across Member States, and are experienced at the local and national level, they are "a global issue that needs to be addressed in a transnational context". RAND Europe undertook an independent evaluation of the current Strategy and its Action Plans, addressing four research objectives:
• To assess barriers and facilitators to the implementation of objectives and priorities at EU and Member State level
• To assess the relevance and influence of the Strategy with respect to national drugs policy and legislation
• To assess possible impact on the drugs situation in the EU
• To identify key aspects and recommendations for future EU Drugs Strategies
• To assess barriers and facilitators to the implementation of objectives and priorities at EU and Member State level
• To assess the relevance and influence of the Strategy with respect to national drugs policy and legislation
• To assess possible impact on the drugs situation in the EU
• To identify key aspects and recommendations for future EU Drugs Strategies